{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:50:33Z","timestamp":1754153433119,"version":"3.41.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1136\/ijgc-2022-003361","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T12:20:45Z","timestamp":1654777245000},"page":"1025-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-6815","authenticated-orcid":false,"given":"Karen","family":"Madland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Bjorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milada Cvancarova","family":"Sm\u00e5stuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"D\u00f8rum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Vistad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003361_bb0010","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003361_bb0015","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/aogs.13199","article-title":"A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway","volume":"96","author":"Vistad","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1136\/ijgc-2022-003361_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003361_bb0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003361_bb0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejogrb.2017.01.025","article-title":"The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials","volume":"210","author":"Leeson","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2022-003361_bb0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"journal-title":"Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft: Helsedirektoratet","year":"2021","key":"10.1136\/ijgc-2022-003361_bb0040"},{"key":"10.1136\/ijgc-2022-003361_bb0045","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/aogs.13396","article-title":"Gynecological cancer patients' attitudes toward follow-up care after cancer treatment: do preferences reflect patients' experience? A cross-sectional questionnaire study","volume":"97","author":"Fidjeland","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1136\/ijgc-2022-003361_bb0050","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003361_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/IGC.0b013e3181a1cc02","article-title":"Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: a retrospective Italian multicentric study","volume":"19","author":"Gadducci","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0060","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/IGC.0b013e318212b87d","article-title":"No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study","volume":"21","author":"Geurts","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2010.01.014","article-title":"Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?","volume":"117","author":"Tanner","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003361_bb0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/IGC.0000000000001040","article-title":"Outcomes and cost analysis of surveillance strategies after initial treatment for women with recurrent ovarian cancer","volume":"27","author":"Alexander","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0075","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/sj.bjc.6605963","article-title":"The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review","volume":"103","author":"Rettenmaier","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0080","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003361_bb0085","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"journal-title":"Veileder I gynekologisk onkologi 2021","year":"2021","key":"10.1136\/ijgc-2022-003361_bb0090"},{"key":"10.1136\/ijgc-2022-003361_bb0095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1148\/rg.312105713","article-title":"Role of FDG PET\/CT in staging of recurrent ovarian cancer","volume":"31","author":"Son","year":"2011","journal-title":"Radiographics"},{"key":"10.1136\/ijgc-2022-003361_bb0100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.21873\/anticanres.14180","article-title":"Positron emission tomography\/computed tomography in platinum-sensitive recurrent ovarian cancer: a single-center Italian study","volume":"40","author":"Gadducci","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2022-003361_bb0105","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0110","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003361_bb0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (chorus): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003361_bb0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003361_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43018-020-00166-5","article-title":"Advances in ovarian cancer, from biology to treatment","volume":"2","author":"McMullen","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1136\/ijgc-2022-003361_bb0130","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaoncol.2016.1842","article-title":"Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer","volume":"2","author":"Esselen","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24008235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24008235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:27:15Z","timestamp":1753234035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24008235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1048891X24008235"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003361","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}